10-Q: QHSLab Reports Q3 2026 Results Amidst Going Concern Doubts

QHSLab, Inc. filed its Q3 2026 10-Q, revealing a revenue decrease in the quarter, continued net losses, and significant concerns about its ability to continue as a going concern.

Summary

• QHSLab, Inc. reported its Q3 2026 results, showing a decrease in quarterly revenue to $677,172 from $737,066 in the prior year period, primarily due to lower allergy diagnostic and immunotherapy sales.
• For the nine months ended September 30, 2026, revenue increased to $2,253,347 from $1,987,931 in the prior year, driven by a 63.9% increase in Integrated Service Program (ISP) revenue.
• The company reported a net loss of $53,145 for the three months ended September 30, 2026, and a net loss of $119,021 for the nine months ended September 30, 2026.
• Despite revenue growth in ISP, overall operating expenses increased, leading to an operating loss of $99,539 for the nine months ended September 30, 2026, compared to an operating income of $95,738 in the prior year.
• The company's accumulated deficit stands at $4,022,572 as of September 30, 2026.
• Cash and cash equivalents decreased significantly to $190,464 from $636,157 at the end of 2025, with $334,989 used in operating activities during the first nine months of 2026.
• Management has identified deficiencies in disclosure controls and procedures due to a lack of adequate personnel with financial reporting experience.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the continued net losses, declining revenue in certain segments, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern, despite some positive trends in specific service areas.

Positives

• Integrated Service Program (ISP) revenue increased by 63.9% to $1,287,692 for the nine months ended September 30, 2026, indicating strong growth in this service area.
• Gross margin improved to 69.2% for the three months ended September 30, 2026, from 67.0% in the prior year period, and from 66.5% to 67.9% for the nine-month periods.
• The company implemented changes to vendor relationships expected to reduce the cost of allergy diagnostic kits by 10-13%, potentially improving future gross margins.
• Interest expense significantly decreased due to the conversion and settlement of loans, from $194,894 in the nine months of 2025 to $19,482 in the same period of 2026.
• The company has substantially reduced its outstanding debt obligations.
• Positive working capital of $271,994 was maintained as of September 30, 2026.

Negatives

• Revenue for the three months ended September 30, 2026, decreased by 8.1% to $677,172 from $737,066 in the prior year.
• The company reported a net loss of $53,145 for the three months and $119,021 for the nine months ended September 30, 2026.
• Operating expenses, particularly general and administrative and sales and marketing, increased significantly, contributing to an operating loss of $99,539 for the nine months ended September 30, 2026.
• Cash and cash equivalents decreased by $445,693 during the nine months ended September 30, 2026, to $190,464.
• The company has an accumulated deficit of $4,022,572 as of September 30, 2026.
• Disclosure controls and procedures were found to be ineffective due to a lack of adequate personnel with financial reporting experience.

Risks

• Substantial doubt exists regarding the Company's ability to continue as a going concern due to its history of losses, negative operating cash flows, and accumulated deficit.
• The company's ability to continue operations is dependent upon achieving sustainable positive operating cash flows or obtaining additional financing.
• Access to future funding may not be available on commercially reasonable terms, if at all.
• Changes in healthcare reimbursement policies by government agencies and insurance providers could adversely affect clients' ability to generate revenues, reducing demand for QHSLab's products and services.
• The company's reliance on a few key customers for a significant portion of its revenue and accounts receivable presents a concentration of credit risk.
• Future utilization of net operating loss carryforwards may be subject to substantial annual limitations due to ownership change limitations, potentially leading to expiration before full utilization.

Future Outlook

Management is focused on improving operating efficiency, expanding recurring revenues, and achieving sustainable profitability. The continued growth of the Integrated Service Program and investment in the technology platform are expected to support greater operating leverage. However, the company has not yet demonstrated sustained profitability from operations, and substantial doubt remains regarding its ability to continue as a going concern. Additional financing may be required if operating results or cash collections do not meet expectations.

Management Comments

• Management is evaluating the extent to which seasonal ordering patterns, physician practice economics, and changes in healthcare insurance affordability and reimbursement policies may have contributed to reduced customer demand.
• Management anticipates that cost reductions in allergy diagnostic kits will contribute favorably to gross margins in future periods.
• Management continues to evaluate its administrative cost structure and implement expense management measures while maintaining the personnel, professional services, and corporate infrastructure necessary to support the Company's operations and regulatory reporting obligations.
• Management continues to focus on improving operating cash flow through disciplined expense management, timely collection of accounts receivable, growth in recurring revenues, and improvements in gross margins.
• Management believes the reduction in debt has strengthened the Company's financial flexibility and reduced future debt servicing requirements.
• Management intends to prioritize funding operations through internally generated cash flows and the collection of outstanding receivables while maintaining a disciplined approach to expenditures.

Industry Context

StockSavvy.ai notes that QHSLab operates in the evolving healthcare technology sector, characterized by a shift towards value-based care and digital health solutions. The company's focus on remote patient monitoring and clinical decision support aligns with industry trends, but its financial performance is heavily influenced by healthcare reimbursement policies, a common challenge for companies in this space.

Comparison to Industry Standards

• The company's revenue growth in its Integrated Service Program (ISP) of 63.9% for the nine months ended September 30, 2026, is strong, but overall revenue declined in the third quarter.
• The persistent net losses and accumulated deficit are a concern, especially when compared to more established, profitable players in the digital health and health tech sectors.
• The company's disclosure of ineffective internal controls due to a lack of personnel is a significant red flag, contrasting with industry best practices for robust financial reporting and governance.
• The substantial doubt about the going concern status is a critical issue that differentiates QHSLab from companies with more stable financial footing and predictable access to capital.

Corporate Governance

Legal Proceedings

• There are no pending or threatened legal proceedings as of September 30, 2026.

Related Party Transactions

• Amounts due to related parties consist of cash advances received from the Company's principal shareholder, some of which are interest-free and due on demand.
• A portion of the advances has been converted into a loan to the principal shareholder at 10% per annum, maturing March 31, 2027.
• As of September 30, 2026, $97,816 was due to a related party, included in current liabilities.
• The Company's CEO and principal shareholder is also a shareholder of MedScience and receives compensation for services provided to MedScience.

Stakeholder Impact

• Shareholders: Potential dilution from future equity issuances, continued uncertainty regarding profitability and going concern status.
• Creditors: Increased risk due to going concern doubts, though debt has been substantially reduced.
• Employees: Potential impact on job security and morale due to financial instability and ineffective internal controls.
• Customers (Physician Practices): Continued reliance on QHSLab's services, but potential impact from company's financial health and evolving reimbursement policies affecting their own revenue.

Next Steps

• Management will continue to evaluate opportunities to strengthen liquidity and capital resources.
• Management will continue to evaluate available financing alternatives based on liquidity requirements, anticipated operating cash flows, financing costs, and shareholder interests.
• Management will continue to reevaluate the ability to add personnel and implement improved review procedures as they can be supported by business growth.

Key Dates

Recommendation

The filing indicates significant financial distress, including a net loss, declining quarterly revenue, and a stated substantial doubt about the company's ability to continue as a going concern. Ineffective internal controls further exacerbate these concerns. While there is growth in specific service areas, the overall financial picture and operational risks outweigh these positives, suggesting a sell recommendation for seasoned investors.

Keywords

healthcare technology, digital health, value-based care, personalized medicine, remote patient monitoring, allergy diagnostics, immunotherapy, clinical decision support